Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics Inc (PSTV)
NASDAQ:PSTV
PSTV Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PSTV Stock 12 Month Forecast
Average Price Target
$6.17
▲(681.01% Upside)
| Highest Price Target$9.00 | Average Price Target$6.17 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Maxim Group
Reiterated
03/31/25
H.C. Wainwright
Reiterated
03/28/25
D. Boral Capital
Initiated
03/17/25
Ascendiant
$20→$19
Buy
2305.06%
Upside
Reiterated
12/07/24
We are adjusting our 2024 estimates for revenue (grant revenue) to $6 million, from $5 million, and for EPS to $(2.21) from $(2.00). Focus on RNL for oncology: The company is focused on its clinical stage oncology pipeline. The lead drug is a Rhenium-186-chelated NanoLiposome (Rhenium (186Re) Obisbemeda), is initially being developed for recurrent glioblastoma (GBM) but has expanded to other cancers indications. Glioblastoma is a rare, incurable, and fatal brain cancer with no good treatment options. RNL is currently being evaluated in a NIH/NCI-supported Phase 2 clinical trial in the U.S. RNL is infused directly into the brain tumor to deliver very high therapeutic doses of radiation to patients whose cancer has recurred following treatments with surgery, chemotherapy, and radiation.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Maxim Group
Reiterated
03/31/25
H.C. Wainwright
Reiterated
03/28/25
D. Boral Capital
Initiated
03/17/25
Ascendiant
$20→$19
Buy
2305.06%
Upside
Reiterated
12/07/24
We are adjusting our 2024 estimates for revenue (grant revenue) to $6 million, from $5 million, and for EPS to $(2.21) from $(2.00). Focus on RNL for oncology: The company is focused on its clinical stage oncology pipeline. The lead drug is a Rhenium-186-chelated NanoLiposome (Rhenium (186Re) Obisbemeda), is initially being developed for recurrent glioblastoma (GBM) but has expanded to other cancers indications. Glioblastoma is a rare, incurable, and fatal brain cancer with no good treatment options. RNL is currently being evaluated in a NIH/NCI-supported Phase 2 clinical trial in the U.S. RNL is infused directly into the brain tumor to deliver very high therapeutic doses of radiation to patients whose cancer has recurred following treatments with surgery, chemotherapy, and radiation.
Best Analysts Covering Plus Therapeutics
Which Analyst Should I Follow If I Want to Buy PSTV and Sell After:
1 Month
xxx
Success Rate
6/17 ratings generated profit
Average Return
-3.80%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 35.29% of your transactions generating a profit, with an average return of -3.80% per trade.
3 Months
xxx
Success Rate
2/17 ratings generated profit
Average Return
-22.17%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 11.76% of your transactions generating a profit, with an average return of -22.17% per trade.
1 Year
Success Rate
1/17 ratings generated profit
Average Return
-55.82%
reiterated a buy rating 10 days ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -55.82% per trade.
2 Years
xxx
Success Rate
0/17 ratings generated profit
Average Return
-71.92%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -71.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PSTV Analyst Recommendation Trends
Rating
May 24
Aug 24
Oct 24
Nov 24
Mar 25
Strong Buy
6
8
7
8
8
Buy
0
0
0
0
0
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
8
7
8
9
Each month's total comprises the sum of three months' worth of ratings.
PSTV Financial Forecast
PSTV Stock Forecast FAQ
What is PSTV’s average 12-month price target, according to analysts?
Based on analyst ratings, Plus Therapeutics Inc’s 12-month average price target is $6.17.
What is PSTV’s upside potential, based on the analysts’ average price target?
Plus Therapeutics Inc has 681.01% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PSTV a Buy, Sell or Hold?
Plus Therapeutics Inc has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Plus Therapeutics Inc’s price target?
The average price target for Plus Therapeutics Inc is $6.17. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.00 ,the lowest forecast is $4.00. The average price target represents 681.01% Increase from the current price of $0.79.
The highest analyst price target is $9.00 ,the lowest forecast is $4.00. The average price target represents 681.01% Increase from the current price of $0.79.
What do analysts say about Plus Therapeutics Inc?
Plus Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of PSTV?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.